序号 |
标题 |
次数 |
作者 |
发布时间 |
75691 |
CAS: 2259318-55-1 - DBCO-(PEG2-VC-PAB-MMAE)2 |
65 |
WYQ |
2024-12-19 |
75692 |
CAS: 2768446-73-5,DBCO-Val-Cit-PAB-MMAE |
78 |
WYQ |
2024-12-19 |
75693 |
MC-vc-PAB-C6-a-amanitin, ADC试剂 |
69 |
kx |
2024-12-19 |
75694 |
cas:663598-98-9,2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate,ADC定制 |
89 |
wyh |
2024-12-19 |
75695 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
87 |
zyl |
2024-12-19 |
75696 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate,ADC定制 |
95 |
wyh |
2024-12-19 |
75697 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
118 |
zyl |
2024-12-19 |
75698 |
Gly3-vc-PAB-MMAE, ADC试剂 |
102 |
kx |
2024-12-19 |
75699 |
CAS: 1869126-64-6, Azido-PEG4-Val-Cit-PAB-MMAE |
86 |
WYQ |
2024-12-19 |
75700 |
cas:2353409-54-6 , Mal-amido-PEG8-Val-Gly,ADC定制 |
104 |
wyh |
2024-12-19 |
75701 |
Azido-PEG4-Val-Ala-PAB-PNP |
98 |
zyl |
2024-12-19 |
75702 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
78 |
h |
2024-12-19 |
75703 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid,ADC定制 |
89 |
wyh |
2024-12-19 |
75704 |
CAS: 1343476-44-7,Val-Ala-PAB-OH |
78 |
WYQ |
2024-12-19 |
75705 |
MC-PBD, ADC试剂 |
87 |
kx |
2024-12-19 |
75706 |
Mal-Val-Ala-PAB的介绍 |
90 |
zyl |
2024-12-19 |
75707 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
79 |
h |
2024-12-19 |
75708 |
Azide-PEG3-Val-Cit-PAB-MMAF,叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
82 |
WYQ |
2024-12-19 |
75709 |
Arm-DOTA-B72.3 |
77 |
h |
2024-12-19 |
75710 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
92 |
zyl |
2024-12-19 |
75711 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
126 |
h |
2024-12-19 |
75712 |
1801838-28-7,Mc-vc-PAB-SN38,化合物MC-VC-PAB-SN38 |
87 |
kx |
2024-12-19 |
75713 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
88 |
h |
2024-12-19 |
75714 |
CAS: 863971-17-9,MC-Val-Cit-PAB-MMAF |
109 |
WYQ |
2024-12-19 |
75715 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
122 |
zyl |
2024-12-19 |
75716 |
DBCO-PEG4-vc-PAB-MMAE, ADC试剂 |
112 |
kx |
2024-12-19 |
75717 |
1884578-00-0,Boc-PEG4-Val-Ala-PAB-PNP,ADC定制 |
114 |
wyh |
2024-12-19 |
75718 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
76 |
h |
2024-12-19 |
75719 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
94 |
h |
2024-12-19 |
75720 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB,ADC定制 |
114 |
wyh |
2024-12-19 |
75721 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
91 |
h |
2024-12-19 |
75722 |
Azido-PEG4-MMAE,抗体药物偶联物(ADCs) |
123 |
WYQ |
2024-12-19 |
75723 |
1626359-62-3,SPDB-DM4, ADC试剂 |
81 |
kx |
2024-12-19 |
75724 |
Acid-PEG4-Val-Cit-PAB-MMAE,包含PEG链和MMAE等部分 |
87 |
WYQ |
2024-12-19 |
75725 |
cas:159857-70-2,MC-Val-Cit-Doxorubicin,ADC定制 |
109 |
wyh |
2024-12-19 |
75726 |
DOTA-(D)Phe(1)-Tyr(3) |
81 |
h |
2024-12-19 |
75727 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
123 |
zyl |
2024-12-19 |
75728 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
124 |
WYQ |
2024-12-19 |
75729 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
80 |
h |
2024-12-19 |
75730 |
CAS: 2762518-86-3 ,NHS ester-PEG4-Val-Cit-PAB-MMAE |
94 |
WYQ |
2024-12-19 |
75731 |
cas:2873452-49-2 ; MC-EVCit-PAB-MMAE,ADC定制 |
112 |
wyh |
2024-12-19 |
75732 |
CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE,内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 |
131 |
WYQ |
2024-12-19 |
75733 |
cas:863971-24-8,Mc-MMAE ,马来酰亚胺基己酰-单甲基澳瑞他汀 E |
168 |
kx |
2024-12-19 |
75734 |
DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 |
84 |
h |
2024-12-19 |
75735 |
cas:2259318-55-1 , DBCO-(PEG2-VC-PAB-MMAE)2,ADC定制 |
96 |
wyh |
2024-12-19 |